Unknown OBSERVATIONAL NCT04473703

Cardiac Adverse Reactions Related to Immune Checkpoint Inhibitor in NSCLC Patients

A Prospective Study of Cardiac Adverse Reactions Related to Immune Checkpoint Inhibitor in Non-Small Cell Lung Cancer Patients

Sponsor: Shanghai Chest Hospital

Conditions Adverse Reactions Cardiac Event Immune Checkpoint Inhibitor Non-Small Cell Lung Cancer Patients

Interventions renin-angiotensin system inhibitors or angiotensin-receptor-neprilysin inhibitor

Updated 5 times since 2020 Last updated: Jul 15, 2020 Started: Aug 1, 2020 Primary completion: Aug 1, 2022 Completion: Aug 1, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on Adverse Reactions and Cardiac Event, this trial is ongoing. The trial is conducted by Shanghai Chest Hospital and has accumulated 5 data snapshots since 2020. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown
Jul 2024 — Sep 2024 [monthly]

Unknown

Status: Unknown Status → Unknown
Sep 2023 — Jul 2024 [monthly]

Unknown Status

Status: Not Yet Recruiting → Unknown Status
Jan 2021 — Sep 2023 [monthly]

Not Yet Recruiting
Aug 2020 — Jan 2021 [monthly]

Not Yet Recruiting

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Shanghai Chest Hospital

Data source: Shanghai Chest Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.